Key result
The abstract describes the methodology for a retrospective cohort study assessing the association of concurrent interacting medications with bleeding and thrombotic events in patients on rivaroxaban, but reports no results.
Why the study?
Does concurrent use of CYP3A4 and P-gp inhibitors increase the risk of bleeding and thrombotic events in patients managed on rivaroxaban?
Cohort
Does concurrent use of CYP3A4 and P-gp inhibitors increase the risk of bleeding and thrombotic events in patients managed on rivaroxaban?
Answers are grounded in this paper and cite their sources.
Methods for assessing rivaroxaban drug interactions described without results; leaves open real-world bleeding and thrombosis associations.
Background/Introduction: Rivaroxaban is a substrate of cytochrome P450 3A4 (CYP3A4) and the P-gp efflux transport system. Despite labeled warnings, real-world evidence of impact of co-administration of drugs that affect the CYP3A4 and P-gp systems on clinical outcomes is lacking. Purpose: To determine the association of CYP3A4 and P-gp inhibitor (CIM) use with the time to bleeding and thrombotic events (TE) (i.e., stroke/TIA, deep venous thrombosis, and pulmonary embolism) in patients managed on rivaroxaban. Methods: This was a retrospective cohort study that combined prescription and medical claims data from a 250,000 member regional health plan located in the central United States from 2011 through 2016. Outpatient pharmacy claims were used to characterize initiation and longitudinal exposure to rivaroxaban and CYP3A4/P-gp inhibitors. The first prescription for rivaroxaban during the enrollment period served as the index date. Bleeding and TE were captured in medical claims using ICD-9 and ICD-10 codes during the 12-month post-index period. Continuous health plan enrollment was verified for 12 months pre and post index date. Time to bleeding was described using Kaplan-Meier analysis. A Cox proportional hazards model adjusting for differences among the treatment cohorts was used to assess the risk of bleeding. Covariates in the adjusted analyses included age, gender, pre-index warfarin use (yes/no), bleeding during the pre-index period (yes/no), and Charlson Comorbidity Index (CCI) score.
No takes yet. Share an insight, caveat, or question.
Michel et al. (2018) conducted a cohort in Patients managed on rivaroxaban. Concurrent interacting medications (CYP3A4 and P-gp inhibitors) was evaluated on Time to bleeding and thrombotic events (stroke/TIA, deep venous thrombosis, and pulmonary embolism). The abstract describes the methodology for a retrospective cohort study assessing the association of concurrent interacting medications with bleeding and thrombotic events in patients on rivaroxaban, but reports no results.
Synapse has enriched 10 related papers. Consider them for comparative context: